Advances in the understanding of cancer immunotherapy

BJU International

Volumn 116, Issue 3, 2015, Pages 321-329

  Shore, Neal D ^a  

^a Carolina Urologic Research Center   (United States)

Author keywords

cancer; checkpoint inhibitor; cytokine; immunoediting; immunotherapy; monoclonal antibody; therapeutic cancer vaccine

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BCG VACCINE; CANCER VACCINE; CETUXIMAB; GLYCOPROTEIN GP 100; IMMUNOMODULATING AGENT; INTERFERON; INTERLEUKIN 2; IPILIMUMAB; MONOCLONAL ANTIBODY; NIVOLUMAB; PLACEBO; RILIMOGENE GALVACIREPVEC; SIPULEUCEL T; TRASTUZUMAB; CYTOKINE;

BLADDER CANCER; CANCER GROWTH; CANCER IMMUNOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CHRONIC MYELOID LEUKEMIA; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; FOLLICULAR LYMPHOMA; HAIRY CELL LEUKEMIA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNE RESPONSE; INOPERABLE CANCER; KAPOSI SARCOMA; KIDNEY CARCINOMA; MELANOMA; METASTATIC COLORECTAL CANCER; METASTATIC MELANOMA; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TUMOR ESCAPE; TUMOR IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS;

ANTIBODIES, MONOCLONAL; CANCER VACCINES; CYTOKINES; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 84938972107     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12692     Document Type: Review

References (44)

1. Abbas AK, Lichtman AH,. Basic Immunology: Functions and Disorders of the Immune System, 3rd edn. Philadelphia: Saunders Elsevier, 2011
2. Suresh R, Mosser DM,. Pattern recognition receptors in innate immunity, host defense, and immunopathology. Adv Physiol Educ 2013; 37: 284-91
3. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C,. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4: 905-13
4. Le Mire L, Hollowood K, Gray D, Bordea C, Wojnarowska F,. Melanomas in renal transplant recipients. Br J Dermatol 2006; 154: 472-77
5. Collett D, Mumford L, Banner NR, Neuberger J, Watson C,. Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant 2010; 10: 1889-96
6. Burgi A, Brodine S, Wegner S, et al. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer 2005; 104: 1505-11
7. Sharma P, Shen Y, Wen S, et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A 2007; 104: 3967-72
8. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 203-13
9. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-64
10. Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S,. Immunotherapy of cancer in 2012. CA Cancer J Clin 2012; 62: 309-35
11. PROVENGE (sipuleucel-T) prescribing information. 2011. Available at: http://www.provenge.com/pdf/prescribing-information.pdf. Accessed 12 September 2013
12. YERVOY (ipilimumab) prescribing information. 2013. Available at: http://packageinserts.bms.com/pi/pi-yervoy.pdf. Accessed 12 September 2013
13. Hanahan D, Weinberg RA,. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74
14. Dunn GP, Koebel CM, Schreiber RD,. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006; 6: 836-48
15. Schreiber RD, Old LJ, Smyth MJ,. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-70
16. Sabry M, Lowdell MW,. Tumor-primed NK cells: waiting for the green light. Front Immunol 2013; 4: 408. doi: 10.3389/fimmu.2013.00408
17. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S,. Functions of natural killer cells. Nat Immunol 2008; 9: 503-10
18. Grebe KM, Yewdell JW, Bennink JR,. Heterosubtypic immunity to influenza A virus: where do we stand? Microbes Infect 2008; 10: 1024-29
19. Drake CG,. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 2010; 10: 580-93
20. Reinhardt RL, Khoruts A, Merica R, Zell T, Jenkins MK,. Visualizing the generation of memory CD4 T cells in the whole body. Nature 2001; 410: 101-5
21. Gulley JL,. Therapeutic vaccines: the ultimate personalized therapy? Hum Vaccin Immunother 2013; 9: 219-21
22. Hammarlund E, Lewis MW, Hansen SG, et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 2003; 9: 1131-37
23. Lesterhuis WJ, Haanen JB, Punt CJ,. Cancer immunotherapy-revisited. Nat Rev Drug Discov 2011; 10: 591-600
24. National Cancer Institute. NCI dictionary of cancer terms: immunotherapy. Available at: http://www.cancer.gov/dictionary?print=1&cdrid=45729. Accessed 12 September 2013
25. Mellman I, Coukos G, Dranoff G,. Cancer immunotherapy comes of age. Nature 2011; 480: 480-89
26. Bachmann MF, Oxenius A,. Interleukin 2: from immunostimulation to immunoregulation and back again. EMBO Rep 2007; 8: 1142-48
27. Lotze M,. Interleukin therapy. In, DeVita VT, Lawrence TS, Rosenberg SA, eds, Cancer: Principles & Practice of Oncology, 9th edn. Philadelphia: LWW, 2011: 469-81
28. Rescigno M, Avogadri F, Curigliano G,. Challenges and prospects of immunotherapy as cancer treatment. Biochim Biophys Acta 2007; 1776: 108-23
29. Dantzer R, Kelley KW,. Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun 2007; 21: 153-60
30. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92
31. Lee SC, Srivastava RM, López-Albaitero A, Ferrone S, Ferris RL,. Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. Immunol Res 2011; 50: 248-54
32. Srivastava RM, Lee SC, Andrade Filho PA, et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res 2013; 19: 1858-72
33. Pardoll DM,. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-64
34. Sharma P, Wagner K, Wolchok JD, Allison JP,. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 2011; 11: 805-12
35. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23
36. Madan RA, Gulley JL, Kantoff PW,. Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies. Cancer J 2013; 19: 50-8
37. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-22
38. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28: 1099-105
39. ClinicalTrials.gov. A randomized, double-blind, phase 3 efficacy trial of PROSTVAC-V/F +/- GM-CSF in men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT01322490. Accessed 12 September 2013
40. Sonpavde G, Kantoff PW,. Immunotherapy for castration-resistant prostate cancer. Urol Clin North Am 2012; 39: 465-81
41. Madan RA, Gulley JL, Fojo T, Dahut WL,. Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist 2010; 15: 969-75
42. Gulley JL, Drake CG,. Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin Cancer Res 2011; 17: 3884-91
43. Jure-Kunkel M, Masters G, Girit E, et al. Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models. Cancer Immunol Immunother 2013; 62: 1533-45
44. Kalbasi A, June CH, Haas N, Vapiwala N,. Radiation and immunotherapy: a synergistic combination. J Clin Invest 2013; 123: 2756-63